(CercleFinance.com) – Sanofi announces that the CHMP of the European Medicines Agency has issued a favorable opinion on the approval of its Dupixent in the European Union for the treatment of moderate to severe nodular prurigo in adults candidate for systemic treatment.
This recommendation is based on data from two pivotal trials which showed that Dupixent significantly improved itching, skin lesions and health-related quality of life in adults with prurigo nodularis.
The European Commission is expected to make its final decision in the coming months. If this indication is approved, Dupixent will be the first and only targeted drug specifically indicated for the treatment of nodular prurigo in the EU.